Pages that link to "Q36577151"
Jump to navigation
Jump to search
The following pages link to Drug insight: rituximab in renal disease and transplantation (Q36577151):
Displaying 50 items.
- The future of biologic agents in the treatment of Sjögren's syndrome (Q24681044) (← links)
- Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets (Q26775103) (← links)
- Nonimmunologic targets of immunosuppressive agents in podocytes (Q26781358) (← links)
- Unraveling the Role of Allo-Antibodies and Transplant Injury (Q28069336) (← links)
- Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis (Q30541740) (← links)
- Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab (Q33420201) (← links)
- Blood disorders typically associated with renal transplantation (Q33421793) (← links)
- Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates (Q33822191) (← links)
- Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (Q33950931) (← links)
- Rituximab therapy in idiopathic membranous nephropathy: a 2-year study (Q34362660) (← links)
- Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group. (Q36028067) (← links)
- New approaches to the treatment of dense deposit disease (Q36860946) (← links)
- The Characteristics and Significance of Locally Infiltrating B Cells in Lupus Nephritis and Their Association with Local BAFF Expression (Q36960116) (← links)
- Latest treatment strategies for membranous nephropathy. (Q37013035) (← links)
- Cancer risk after ABO-incompatible living-donor kidney transplantation (Q37138338) (← links)
- Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients (Q37211086) (← links)
- Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis (Q37297636) (← links)
- Japan's experience with living-donor kidney transplantation across ABO barriers (Q37305391) (← links)
- Rituximab for membranous nephropathy and immune disease: less might be enough (Q37338938) (← links)
- Actin-associated Proteins in the Pathogenesis of Podocyte Injury (Q37402598) (← links)
- Monoclonal antibodies for podocytopathies: rationale and clinical responses (Q37498290) (← links)
- B-cell-directed therapies for autoimmune disease (Q37542901) (← links)
- Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. (Q37626123) (← links)
- Advances in diagnosing and managing antibody-mediated rejection (Q37676032) (← links)
- The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. (Q37704938) (← links)
- ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? (Q37803412) (← links)
- Update on the role of rituximab in kidney diseases and transplant (Q37970443) (← links)
- B-cell-targeted therapy in adult glomerulonephritis (Q38159787) (← links)
- Acute and chronic antibody-mediated rejection in pediatric kidney transplantation (Q38215262) (← links)
- Biologic agents in the treatment of glomerulonephritides (Q38514894) (← links)
- Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study (Q39386528) (← links)
- Treatment of membranous nephropathy: time for a paradigm shift (Q39410091) (← links)
- Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis (Q42122199) (← links)
- An Integrative Approach for the Transplantation of High-Risk Sensitized Patients (Q42951982) (← links)
- The new drugs in development for kidney transplantation (Q43175106) (← links)
- Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice (Q43297973) (← links)
- Non-hepatitis virus associated mixed essential cryoglobulinemia (Q44272976) (← links)
- Hepatitis B reactivation in a renal transplant patient due to a surface antigen mutant strain: a case report. (Q45272430) (← links)
- Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report (Q46369005) (← links)
- Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab (Q46586703) (← links)
- Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution (Q46693469) (← links)
- Transplantation: it may take two to tango and to treat (Q46818722) (← links)
- Rituximab for refractory focal segmental glomerulosclerosis (Q46922097) (← links)
- Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients (Q46937121) (← links)
- Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis (Q46987729) (← links)
- Anti-glomerular basement membrane disease in an HIV-infected patient (Q47569044) (← links)
- Kidney Transplantation for High-Risk Sensitized Patients – The “Heidelberg Algorithm” (Q51579669) (← links)
- Treatment of steroid-resistant nephrotic syndrome in the genomic era (Q57049336) (← links)
- Beneficial effects of rituximab therapy for systemic lupus erythematosus (Q79692141) (← links)
- Cross Reactive Epitope Group antibodies in sensitized kidneys transplant recipients was associated with early acute Antibody Mediated Rejection (Q79815538) (← links)